Reporter’s Notebook: Gene Editing's Long Road from Theory to Therapy

Reporter’s Notebook: Gene Editing's Long Road from Theory to Therapy

Gene editing has fluctuated between promise and reality for a decade. At the 2026 J.P. Morgan Healthcare Conference, that tension hadn’t dissipated, but the tone had shifted. This year’s biggest updates weren’t about platform power or hypotheticals. Instead, they were rooted in clinical data, manufacturability, access, and, most critically, business success.  In these video interviews, I met with the brass of four gene editing companies—Mammoth …